InvestorsHub Logo
Followers 16
Posts 1775
Boards Moderated 0
Alias Born 08/05/2008

Re: None

Sunday, 09/25/2011 7:15:02 AM

Sunday, September 25, 2011 7:15:02 AM

Post# of 430
Novartis study shows QTI571 significantly improved walking distance in patients with life-threatening pulmonary arterial hypertension
http://www.novartis.com/newsroom/media-releases/en/2011/1549437.shtml

Phase III IMPRES study demonstrates potential benefits of QTI571 in patients who remain symptomatic despite treatment with two or more PAH therapies[1]

Evidence indicates that QTI571 targets an underlying cause of PAH by counteracting uncontrolled growth of arterial smooth muscle cells[2]

PAH is a debilitating disease of the heart and lungs affecting up to 260,000 people worldwide[3] leading to heart failure and death[4],[5]







Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVS News